Abstracts Archive - Page 1532 of 2425 - ACR Meeting Abstracts

Abstract Number: 1718 • 2016 ACR/ARHP Annual Meeting
Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis
Fenglong Xie¹, Lang Chen¹, Huifeng Yun², Timothy Beukelman³ and Jeffrey Curtis⁴, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ³Pediatric Rheumatology, University of Alabama-Birmingham, Birmingham, AL, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody and apremilast, an inhibitor of phosphodiesterase 4 are two relatively new agents used for the treatment of…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 1720 • 2016 ACR/ARHP Annual Meeting
Predictive Value of Different Tools for Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, GR Burmester⁴, Siegfried Wassenberg⁵, Benjamin Köhler⁶, Ulrich Kaesser⁷, Marina Backhaus⁸, Harald Burkhardt⁹ and Frank Behrens⁹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumazentrum, Ratingen, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷6Internistische Praxisgemeinschaft am Krankenhaus Balserische Stiftung Gießen, Gießen, Germany, ⁸Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin disease in Europe. Psoriatic arthritis (PsA) is closely associated to Pso; the skin…
Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Augusta Ortolan¹, Giovanni Boschetti², Mariagrazia Lorenzin¹, Giulia Cherobin³, Leonardo Punzi³, Massimo Puato² and Roberta Ramonda³, ¹Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ²Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…
Abstract Number: 1722 • 2016 ACR/ARHP Annual Meeting
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Alexis Ogdie¹, J. Lynn Palmer², Jeffrey D. Greenberg³, Leslie R. Harrold⁴, Daniel H. Solomon⁵, Arthur Kavanaugh⁶, Joel Kremer⁷, Philip J Mease⁸ and Jeffrey R. Curtis⁹, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Albany, NY, ³New York University School of Medicine, New York, NY, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶University of California San Diego, La Jolla, CA, ⁷The Center for Rheumatology, Albany Medical College, Albany, NY, ⁸Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with varied response to therapy. We examined predictors of remission at one year among patients with PsA…
Abstract Number: 1723 • 2016 ACR/ARHP Annual Meeting
Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice
Maria Laura Acosta Felquer¹, Agnes Szentpetery^2,3,4,5, Musaab Elmamoun⁶, Phil Gallagher⁴, Oliver FitzGerald⁷ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁵Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁶Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ⁷St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: The Composite Psoriatic Disease Activity Index (CPDAI), a composite disease outcome measure in psoriatic arthritis (PsA) (1),has proved to be a valid and discriminative…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Lianne S. Gensler¹, Elizabeth C. Hsia², Christopher Gasink², Bruce Randazzo², Dennis Parenti³, Steve Fakharzadeh³, Kehzen L. Tang² and Soumya Chakravarty³, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 1729 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Vibeke Strand¹, Philip J Mease², Iain B McInnes³, Peter Nash⁴, Howard Thom⁵, Matthias Hunger⁶, Kunal Gandhi⁷, Shephard Mpofu⁸ and Steffen Jugl⁸, ¹Stanford University School of Medicine, Palo Alto, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁵University of Bristol, Bristol, United Kingdom, ⁶MAPI Group, Munich, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and infliximab (INF) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. There are…
Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Dalton Sholter¹, Proton Rahman², Maqbool Sheriff³, Michel Zummer⁴, Suneil Kapur⁵, Philip Baer⁶, Michael Starr⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Cathy Tkaczyk¹¹, Francois Nantel¹³ and Allen J Lehman¹², ¹University of Alberta, Edmonton, AB, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…
Abstract Number: 1732 • 2016 ACR/ARHP Annual Meeting
Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice
Majed M. Khraishi¹, Proton Rahman², Alexander Tsoukas³, Suneil Kapur⁴, Milton F. Baker⁵, Niall Jones⁶, Michael Starr⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Francois Nantel¹¹, Allen J Lehman¹⁰, Cathy Tkaczyk¹² and Brendan Osborne¹², ¹Nexus Clinical Research, St Johns, NF, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷McGill University, Pointe-Claire, QC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex rheumatic disease with severity that ranges from mild to severe. The mild form of PsA can be referred…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].